GeneDx Holdings Financials - Benzinga

GeneDx Holdings Corp

WGSNASDAQ

Trade with Public

Trade with Public

$85.73

-1.66-1.89%

Ult. Agg.: Sep 4, 11:10 AM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

GeneDx Holdings Financials

GeneDx Holdings (WGS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate

GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.19) by 105.26 percent. This is a 98 percent decrease over earnings of $0.50 per share from the

Benzinga Newsdesk

PRO
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est

GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.

Benzinga Newsdesk

Why Is GeneDx Stock Surging Thursday?

GeneDx (WGS) shares rebound 12% as bargain hunters move in following a steep post-earnings sell-off. Is the genetic testing leader oversold?

Akanksha Bakshi

PRO
CORRECTION: GeneDx Hldgs Q1 Adj. EPS $(0.28) Misses $(0.01) Estimate, Sales $102.300M Miss $112.956M Estimate

GeneDx Hldgs (NASDAQ:WGS) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.01) by 2700 percent. This is a 203.7 percent decrease over earnings of $0.27 per share from the

Benzinga Newsdesk

PRO
GeneDx Holdings Lowers FY2026 Sales Guidance from $540.000M-$555.000M to $475.000M-$490.000M vs $550.216M Est

GeneDx Holdings (NASDAQ:WGS) lowers FY2026 sales outlook from $540.000 million-$555.000 million to $475.000 million-$490.000 million vs $550.216 million estimate.

Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved